Published in Mol Pharm on February 28, 2013
Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol (2014) 0.85
Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin Transl Immunology (2014) 0.81
Tumor necrosis factor α Inhibition for Alzheimer's Disease. J Cent Nerv Syst Dis (2017) 0.75
Bidirectional apical-basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells. J Cereb Blood Flow Metab (2017) 0.75
Newly Divided Eosinophils Limit Ozone-Induced Airway Hyperreactivity In Non-Sensitized Guinea Pigs. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke (1997) 3.26
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol (2006) 3.08
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci (2006) 2.15
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab (1994) 1.49
TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis (2007) 1.35
Regulation of expression of murine transferrin receptor 2. Blood (2001) 1.35
Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng (2009) 1.33
Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol (2012) 1.25
The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today (2009) 1.24
First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut (2005) 1.22
Expression of IL-10 and TNF-alpha in rats with cerebral infarction after transplantation with mesenchymal stem cells. Cell Mol Immunol (2009) 1.21
Blood-brain barrier genomics. J Cereb Blood Flow Metab (2001) 1.11
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol (2010) 1.04
Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab (2012) 0.97
Rate of 59Fe uptake into brain and cerebrospinal fluid and the influence thereon of antibodies against the transferrin receptor. J Neurochem (1993) 0.96
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos (2010) 0.90
Tumor necrosis factor alpha (TNF-alpha) levels in the brain and cerebrospinal fluid after meningitis induced by Streptococcus pneumoniae. Neurosci Lett (2009) 0.88
Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos (2011) 0.87
Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood (2002) 0.87
Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen but not brain, in vivo in mice. J Drug Target (1995) 0.82
Assembly and budding of influenza virus. Virus Res (2004) 2.90
Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem (2002) 1.73
Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.44
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res (2004) 1.42
Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng (2007) 1.42
Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res (2006) 1.40
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng (2009) 1.33
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res (2009) 1.32
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.30
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus. J Biol Chem (2005) 1.28
Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther (2005) 1.26
Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol (2012) 1.25
D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation (2004) 1.20
Synthesis of pegylated immunonanoparticles. Pharm Res (2002) 1.18
Scavenging of the cofactor lipoate is essential for the survival of the malaria parasite Plasmodium falciparum. Mol Microbiol (2007) 1.14
Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther (2003) 1.11
Dually responsive multiblock copolymers via RAFT polymerization: Synthesis of temperature- and redox-responsive copolymers of PNIPAM and PDMAEMA. Macromolecules (2007) 1.11
GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng (2008) 1.10
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther (2004) 1.09
AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol (2009) 1.09
Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther (2002) 1.07
Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab Dispos (2009) 1.07
Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res (2007) 1.06
Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med (2002) 1.04
Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J Biotechnol (2010) 1.04
Gene delivery in vitro and in vivo from bioreducible multilayered polyelectrolyte films of plasmid DNA. Biomaterials (2008) 1.03
In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med (2003) 1.02
Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med (2004) 1.01
Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther (2002) 1.01
Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab (2002) 1.00
Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther (2003) 1.00
Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm (2010) 0.99
Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem (2008) 0.98
Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab (2012) 0.97
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm (2009) 0.97
Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today (2002) 0.97
Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors. J Control Release (2009) 0.96
Lipid body formation plays a central role in cell fate determination during developmental differentiation of Myxococcus xanthus. Mol Microbiol (2009) 0.96
Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis (2003) 0.95
Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther (2010) 0.95
The blood-brain barrier and neurotherapeutics. NeuroRx (2005) 0.94
Genetic engineering of IgG-glucuronidase fusion proteins. J Drug Target (2010) 0.94
Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. J Neurochem (2002) 0.94
Vascular genomics of the human brain. J Cereb Blood Flow Metab (2002) 0.93
Scientific publications from mainland China, Taiwan, and Hong Kong in integrative and complementary medicine journals: a ten-year literature survey. Am J Chin Med (2011) 0.93
Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos (2010) 0.93
Translational science: what is it and why is it so important? Drug Discov Today (2003) 0.93
Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res (2010) 0.92
Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J Pharmacol Exp Ther (2011) 0.92
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm (2009) 0.92
A versatile approach to reducible vinyl polymers via oxidation of telechelic polymers prepared by reversible addition fragmentation chain transfer polymerization. Biomacromolecules (2007) 0.92
P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport (2003) 0.91
Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. J Neuropathol Exp Neurol (2002) 0.91
Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target (2002) 0.91
Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem (2013) 0.90
Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab Dispos (2010) 0.90
Rat blood-brain barrier genomics. II. J Cereb Blood Flow Metab (2002) 0.89
Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci (2002) 0.89
Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res (2003) 0.88
Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res (2007) 0.88